Alzheimer's Disease and Type 2 Diabetes Mellitus: The Use of MCT Oil and a Ketogenic Diet.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms linking diabetes, brain hypometabolism, and ketogenic dietary approaches in Alzheimer's disease.
PubMed 34830192 · doi:10.3390/ijms222212310
What was done
This paper is a narrative review examining the mechanistic links between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), specifically focusing on brain insulin resistance, impaired glucose metabolism, and the rationale for using medium-chain triglyceride (MCT) oil or a ketogenic diet to provide ketone bodies as an alternative energy substrate for the brain.
What was found
The abstract provides no quantitative data, effect sizes, or counts of clinical studies. It describes conceptual relationships: T2DM is associated with impaired brain insulin signaling, decreased insulin receptors, synaptic deficits, and mitochondrial dysfunction. Brain glucose hypometabolism precedes clinical AD symptoms, whereas ketone metabolism remains preserved, supporting the therapeutic rationale for ketone-inducing dietary strategies.
Why it matters
Brain glucose hypometabolism and insulin resistance are recognized early features of Alzheimer's disease. This review summarizes the biological justification for testing ketogenic therapies and MCT supplementation to bypass defective glucose pathways.
Limits
The abstract describes a narrative review presenting mechanistic hypotheses without reporting new clinical data, meta-analytic pooling, sample sizes, or systematic review methodology to evaluate clinical efficacy in humans.
Cited by
- supports In Alzheimer's disease, neurons suffer from impaired glucose metabolism due to brain insulin resistance, but ketone bodies provide an alternative energy substrate.